IO Biotech, Inc. (IOBT) Dividend History

IO Biotech, Inc. (IOBT) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary immune modulation platform, referred to as Immuno-Oncology Biotech (IOBT), to design therapies that stimulate the body's immune system to target disease more effectively. Founded to advance personalized and combination immune treatments, IO Biotech aims to improve patient outcomes through its novel therapeutic candidates.

Ole Maaloes Veh 3, Copenhagen, G7, 2200
Phone: (457) 070-2980
Website: https://www.iobiotech.com

Dividend History

IO Biotech, Inc. currently does not pay dividends

Company News

  • IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

    IO Biotech, a clinical-stage biopharmaceutical company, presented new data at the AACR 2025 Annual Meeting, showcasing the dual mechanism and immune activation of its cancer vaccines IO102-IO103 and IO170.

    GlobeNewswire Inc.
  • Top 5 Health Care Stocks That May Crash This Month

    As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. SOPHiA GENETICS SA (NASDAQ: SOPH) On Jan. 8, SOPHiA GENETICS announced a collaboration with Exactis Innovation on multimodal data analytics. The company’s stock jumped around 14% over the past six months and has ...

    Benzinga
    Featured Companies: CLSD INO SOPH
  • IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

    IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.

    Zacks Investment Research
    Featured Companies: AKRO MRK
Page data last updated 07/25/2025 16:04:45 UTC